Sana Biotechnology, Inc. (SANA) Financial Analysis & Valuation | Quarter Chart
Sana Biotechnology, Inc. (SANA)
SANAPrice: $3.27
Fair Value: 🔒
🔒score
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiov... more
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicine... more
Description
Shares
| Market Cap | $871.32M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Steven D. Harr |
| IPO Date | 2021-02-04 | CAGR | — |
| Employees | 194 | Website | www.sana.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
SANA chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.04B | P/E Ratio | -3.5 |
| Forward P/E | -7.19 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 5.14 |
| P/CF Ratio | -5.75 | P/FCF Ratio | -6.02 |
| EPS | $-0.96 | EPS Growth 1Y | -17.24% |
| EPS Growth 3Y | -32.87% | EPS Growth 5Y | -51.02% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.42% | ROA | -0.59% |
| ROCE | -0.56% | Current Ratio | 1.89 |
| Quick Ratio | 1.89 | Cash Ratio | 0.91 |
| Debt/Equity | 0.49 | Interest Coverage | — |
| Altman Z Score | -5.51 | Piotroski Score | 1 |